Fibrocell Science Inc

Fibrocell Science — Investor Presentation (January 2016)

21 slides from Fibrocell Science's investor presentation, Jan 8, 2016

  1. Slide 1: Corporate Presentation January 8, 2016

    Corporate Presentation January 8, 2016

  2. Slide 2: Forward-Looking Statements

    This presentation contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. All statements that are not historical facts are hereby identified as forward-looking statements for this purpose and include, among

  3. Slide 3: Company Highlights

    Company Highlights • Cell and gene therapy company developing a pipeline of autologous biologics—based on a proprietary fibroblast platform—for localized treatment of connective tissue and joint diseases • Phase II azficel-T sBLA program for Chronic Dysphonia Phase II data expected in 2Q16 • FCX-00

  4. Slide 4: Autologous Fibroblasts as a Platform for Therapy

    Autologous Fibroblasts as a Platform for Therapy • Fibroblasts repair tissue infrastructure by producing extracellular matrix proteins including collagen and growth factors •Most common cell in skin and connective tissue •Key advantages of our autologous fibroblast/gene-therapy approach Localized i

  5. Slide 5: Two Product Engines – Multiple Therapeutics in Development

    Two Product Engines – Multiple Therapeutics in Development 5 Dermal fibroblast cells are removed from patient. The fibroblasts are expanded in the laboratory. The expanded fibroblasts are administered into the patient–delivering localized therapy that is compatible with the patient’s unique biology.

  6. Slide 6: Development Pipeline

    Development Pipeline 6 Personalized Biologics Indication Product Development Pre-Clinical Development Phase I Phase II Phase III azficel-T sBLA* Chronic Dysphonia FCX-007 √ Orphan Product Candidate Recessive Dystrophic Epidermolysis Bullosa (RDEB) FCX-013 √ Linear Scleroderma New ECC Program√ Chroni

  7. Slide 7: Chronic Dysphonia due to Vocal Cord Scarring

    Chronic Dysphonia due to Vocal Cord Scarring 7 Disease Current Treatments Epidemiology Damage to the fibroblast layer causes scarring and edema, which limits air flow and results in severe and significant limitations in voice quality, often loss of voice Current treatments only address symptoms: • V

  8. Slide 8: Clinical Data Support Our Approach in Chronic Dysphonia

    Clinical Data Support Our Approach in Chronic Dysphonia Positive Phase I clinical trial results published in peer-reviewed journal2 • Injection of azficel-T into scarred fold lamina propria layer was found to be safe and well-tolerated in trial (n=5) All patients completed the trial No serious adv

  9. Slide 9: Chronic Dysphonia—Phase II Trial

    Chronic Dysphonia—Phase II Trial 9 • Fully enrolled 20+ subjects One dose per vocal fold per month x 3 treatments Dosing completed •Double-blind, randomized, placebo-controlled • Four-month efficacy endpoint on three different scales: Voice Handicap Index (validated) Mucosal Wave Grade GRBAS (g

  10. Slide 10: Recessive Dystrophic Epidermolysis Bullosa

    Recessive Dystrophic Epidermolysis Bullosa 10 Disease Current Treatments Epidemiology • Cause: A mutation in the COL7A1 gene that encodes for COL7 • Devastating, progressive, painful blistering disease that leads to death • Diagnosed at infancy • High mortality rate • Current treatments only address

  11. Slide 11: FCX-007 Providing Hope for RDEB Patients

    FCX-007 Providing Hope for RDEB Patients 11 RDEB patients do not produce type VII collagen (COL7) due to mutation in COL7A1 gene Main component of anchoring fibrils that connect skin layers FCX-007 is an autologous human dermal fibroblast transduced with a lentiviral (LV) vector containing the gene

  12. Slide 12: COL7 Expression Confirmation

    COL7 Expression Confirmation 12 COL7 Trimer Culture supernatant evaluated for COL7 expression • ELISA assay indicates virus dose-dependent protein expression • Trimeric form of COL7 produced by RDEB patient fibroblasts transduced with LV-COL7

  13. Slide 13: FCX-007 In Vitro Results Summary

    FCX-007 In Vitro Results Summary 13 Results Suggest* Ability to successfully make the vector Ability for full-scale FCX-007 production Full gene integration into cell genome COL7 is being produced from FCX-007 COL7 produced from FCX-007 is the correct size and structure COL7 produced from FCX-007 is

  14. Slide 14: Positive Pre-Clinical Results & Next Steps

    Positive Pre-Clinical Results & Next Steps Toxicity • Hybrid pharmacology/toxicology study with SCID mice grafted with normal human skin graft and injected with FCX-007 to determine toxicity and systemic distribution of vector • Results  No adverse observations at 2 and 6 weeks post-injection  No

  15. Slide 15: FCX-007 Proposed Clinical Trial Design

    FCX-007 Proposed Clinical Trial Design 15 Title A Phase I/II Trial of FCX-007 (Genetically-Modified Autologous Human Dermal Fibroblasts) for Recessive Dystrophic Epidermolysis Bullosa (RDEB) Statement of Purpose The purpose of this study is threefold: 1) To evaluate the safety of FCX-007 2) To evalu

  16. Slide 16: Linear Scleroderma

    Linear Scleroderma 16 Disease Epidemiology • Excess production of extracellular matrix characterized by skin fibrosis and linear scars • The linear areas of skin thickening may extend to underlying tissue and muscle in children which may impair growth in affected legs and arms or forehead • Lesions

  17. Slide 17: FCX-013 Development Progressing

    FCX-013 Development Progressing 17 •Demonstrated protein expression •Product profile Genetically-modified autologous dermal fibroblasts Gene construct identified, target gene selected Preparing scale-up manufacturing using lentivirus • Animal model in development •Anticipated milestones Proof-of

  18. Slide 18: New ECC with Intrexon

    New ECC with Intrexon 18 • Focused on addressing chronic inflammation and degenerative diseases of the joint  Arthritis (characterized by joint inflammation, pain and decreased range of motion) is the leading cause of disability in the U.S. affecting > 52 million adults and 300,000 children • Colla

  19. Slide 19: Anticipated Milestones & Corporate Information

    Anticipated Milestones & Corporate Information 19 •Unaudited Cash = $29.3 million at 31 Dec 2015  $10 million fee paid to XON in Jan 2016 for new ECC •43.9 million common shares of FCSC outstanding at 30 Sept 2015  5.9 million warrants; 3.2 million options Anticipated Milestones Timing FCX-007 Pha

  20. Slide 20: Company Highlights

    Company Highlights • Cell and gene therapy company developing a pipeline of autologous biologics—based on a proprietary fibroblast platform—for localized treatment of connective tissue and joint diseases • Phase II azficel-T sBLA program for Chronic Dysphonia Phase II data expected in 2Q16 • FCX-00

  21. Slide 21: References

    References 1Data on file. Fibrocell Science, Inc. 2Chhetri, Dinesh, Injection of Cultured Autologous Fibroblasts for Human Vocal Fold Scars. The Laryngoscope 121(4):785-792, 2011. 3 The Dystrophic Epidermolysis Research Association of America (DebRA). DEB brochure, page 6: http://www.debra.org/pdfs/

Fibrocell Science — Investor Presentation (January 2016) on 6ix